Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers

Biochemical Pharmacology

Volumn 92, Issue 3, 2014, Pages 448-456

  Fujita, Wakako ^a   Gomes, Ivone ^a   Dove, Leonard S ^b   Prohaska, David ^b   McIntyre, Gail ^b   Devi, Lakshmi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Furiex Pharmaceuticals Inc   (United States)

Author keywords

Anti diarrhea; Eluxadoline; Irritable bowel syndrome; Loperamide; OR OR heteromer

Indexed keywords

BETA ARRESTIN; CASTOR OIL; DELTA OPIATE RECEPTOR; ELUXADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; LOPERAMIDE; MU OPIATE RECEPTOR; NALTREXONE; IMIDAZOLE DERIVATIVE; LIGAND; PHENYLALANINE; RETINA S ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIARRHEAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; GASTROINTESTINAL TRANSIT; IN VITRO STUDY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MUTANT MOUSE STRAIN; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; CASTOR OIL; DIARRHEA; HUMANS; IMIDAZOLES; LIGANDS; LOPERAMIDE; MALE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PHENYLALANINE; PROTEIN MULTIMERIZATION; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84910609516     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.09.015     Document Type: Article

References (58)

1. Hall EJ, Sykes NP. Analgesia for patients with advanced disease: I. Postgrad Med J 2004;80:148-54.
2. Abul-Husn NS, Sutak M, Milne B, Jhamandas K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br J Pharmacol 2007;151:877-87.
3. Porreca F, Heyman JS, Mosberg HI, Omnaas JR, Vaught JL. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse. J Pharmacol Exp Therap 1987;241:393-400.
4. Szentirmay AK, Kiraly KP, Lenkey N, Lacko E, Al-Khrasani M, Friedmann T, et al. Spinal interaction between the highly selective mu agonist DAMGO and several delta opioid receptor ligands in naive and morphine-tolerant mice. Brain Res Bull 2013;90:66-71.
5. Vaught JL, Takemori AE. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Therap 1979;208:86-90.
6. Vaught JL, Takemori AE. A further characterization of the differential effects of leucine enkephalin, methionine enkephalin and their analogs on morphine-induced analgesia. J Pharmacol Exp Therap 1979;211:280-3.
7. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004;101:5135-9.
8. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci Off J Soc Neurosci 2000;20:RC110.
9. Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA. G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 2011;79:1044-52.
10. Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, et al. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010;3:ra54.
11. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, et al. Facilitation of muopioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron 2011;69:120-31.
12. Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J 2006;8:E118-25.
13. Ananthan S, Saini SK, Dersch CM, Xu H, McGlinchey N, Giuvelis D, et al. 14-Alkoxy- and 14-acyloxypyridomorphinans: mu agonist/delta antagonist opioid analgesics with diminished tolerance and dependence side effects. J Med Chem 2012;55:8350-63.
14. Breslin HJ, Diamond CJ, Kavash RW, Cai C, Dyatkin AB, Miskowski TA, et al. Identification of a dual delta OR antagonist/mu OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d). Bioorg Med Chem Lett 2012;22:4869-72.
15. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 2005;102:19208-13.
16. Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, et al. Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/micro opioid receptor antagonist. Br J Pharmacol 2012;167: 1111-25.
17. Yekkirala AS, Kalyuzhny AE, Portoghese PS. An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands. ACS Chem Biol 2013.
18. Chen W, Chung HH, Cheng JT. Opiate-induced constipation related to activation of small intestine opioid mu2-receptors. World J Gastroenterol: WJG 2012;18:1391-6.
19. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Digest Dis Sci 1984;29: 239-47.
20. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003;56:362-9.
21. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;130:81-4.
22. Meuris B. Observational study of travelers' diarrhea. J Travel Med 1995;2: 11-5.
23. Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013;145:329-3380.
24. Rang HP. Stimulant actions of volatile anaesthetics on smooth muscle. Br J Pharmacol Chemother 1964;22:356-65.
25. Gomes I, Filipovska J, Devi LA. Opioid receptor oligomerization. Detection and functional characterization of interacting receptors. Methods Mol Med 2003;84:157-83.
26. Gomes I, Fujita W, Gupta A, Saldanha AS, Negri A, Pinello CE, et al. Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci USA 2013;110:12072-77.
27. Rozenfeld R, Gupta A, Gagnidze K, Lim MP, Gomes I, Lee-Ramos D, et al. AT1RCB(1)R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J 2011;30:2350-63.
28. Moriya R, Shirakura T, Hirose H, Kanno T, Suzuki J, Kanatani A. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice. Peptides 2010;31:671-5.
29. Poggioli R, Benelli A, Arletti R, Cavazzuti E, Bertolini A. K+ channel openers delay intestinal transit and have antidiarrheal activity. Eur J Pharmacol 1995;287:207-9.
30. Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, et al. Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 2007;282:5116-24.
31. Gomes I, Wardman J, Stockton SD, Devi LA. G protein-coupled receptor signaling. San Rafael: Morgan & Claypool Publishers LLC; 2013.
32. Poole DP, Pelayo JC, Scherrer G, Evans CJ, Kieffer BL, Bunnett NW. Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. Gastroenterology 2011;141:982-91. e1-8.
33. Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand JP, Manara L. Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol 1997;121:375-80.
34. Marcais-Collado H, Uchida G, Costentin J, Schwartz JC, Lecomte JM. Naloxonereversible antidiarrheal effects of enkephalinase inhibitors. Eur J Pharmacol 1987;144:125-32.
35. Fujita W, Gomes I, Devi LA. Revolution in GPCR signaling: opioid receptor heteromers as novel therapeutic targets. Br J Pharmacol 2014.
36. Fujita W, Gomes I, Devi LA. Mu-Delta opioid receptor heteromers: new pharmacology and novel therapeutic possibilities. Br J Pharmacol 2014.
37. Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J Off Publ Fed Am Soc Exp Biol 2007;21:2455-65.
38. Sanchez-Blazquez P, Garcia-Espana A, Garzon J. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Therap 1997;280:1423-31.
39. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999;24:243-52.
40. Harvey JH, Long DH, England PM, Whistler JL. Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers. ACS Med Chem Lett 2012;3:640-4.
41. Lenard NR, Daniels DJ, Portoghese PS, Roerig SC. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 2007;566:75-82.
42. Schiller PW, Fundytus ME, Merovitz L, Weltrowska G, Nguyen TM, Lemieux C, et al. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 1999;42:3520-6.
43. Ammon HV, Phillips SF. Inhibition of ileal water absorption by intraluminal fatty acids. Influence of chain length, hydroxylation, and conjugation of fatty acids. J Clin Investig 1974;53:205-10.
44. Ammon HV, Thomas PJ, Phillips SF. Effects of oleic and ricinoleic acids on net jejunal water and electrolyte movement. Perfusion studies in man. J Clin Investig 1974;53:374-9.
45. Bright-Asare P, Binder HJ. Stimulation of colonic secretion of water and electrolytes by hydroxy fatty acids. Gastroenterology 1973;64:81-8.
46. Tunaru S, Althoff TF, Nusing RM, Diener M, Offermanns S. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. Proc Natl Acad Sci USA 2012;109:9179-84.
47. Angrini M, Leslie JC, Shephard RA. Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behavior. Pharmacol Biochem Behav 1998;59:387-97.
48. Stam R, Croiset G, Akkermans LM, Wiegant VM. Effects of novelty and conditioned fear on small intestinal and colonic motility and behaviour in the rat. Physiol Behav 1995;58:803-9.
49. Stam R, Croiset G, Akkermans LM, Wiegant VM. Behavioural and intestinal responses to novelty in rats selected for diverging reactivity in the open field test. Behav Brain Res 1997;88:231-8.
50. Okano S, Nagaya H, Inatomi N. Novelty stress increases fecal pellet output in Mongolian gerbils: effects of several drugs. J Pharmacol Sci 2005;98: 411-8.
51. Gray AC, Coupar IM, White PJ. Comparison of opioid receptor distributions in the rat ileum. Life Sci 2006;78:1610-6.
52. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999;286:2495-8.
53. Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Therap 2005;314:1195-201.
54. Bohn LM, Raehal KM. Opioid receptor signaling: relevance for gastrointestinal therapy. Curr Opin Pharmacol 2006;6:559-63.
55. Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manage 2009;5:145-51.
56. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic nonmalignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51.
57. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motility Off J Eur Gastrointestinal Motility Soc 2010;22:424-30. e96.
58. Ross GR, Gabra BH, Dewey WL, Akbarali HI. Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Therap 2008;327:561-72.